A mixed-antibody treatment does not protect patients from cognitive decline.
More bad news from drugmakers trying to develop treatments for Alzheimer’s disease: Yesterday, Baxter announced that its mixed-antibody therapy failed to reduce cognitive decline in patients with mild to moderate Alzheimer’s disease. As I reported back in July 2012, the company saw positive results in a small four-patient trial of the treatment. None of these patients showed any cognitive decline, leading some experts to hope that the disease can be stopped or slowed (see “Study Suggests Alzheimer’s Disease Can be Stabilized”). But when Baxter tested its potential treatment—a complex mixture of antibodies harvested from healthy donated blood—in nearly 100-times as many Alzheimer’s patients, the company did not find a rate of decline slower than patients given a placebo.


Apple’s landmark $ 1 billion damages award over Samsung has been partially vacated by presiding judge Lucy Koh, FOSS Patents reports. The judge has orders just north of $ 450 million be struck from the $ 1 billion total, an amount which relates to 14 Samsung products involved in the case, pending a new trial to determine appropriate damages for those specific devices.


Some people really don’t like a recent promotion from
This evening at
Likened to a 

Apple and Samsung’s whirlwind legal battle in San Jose, California has finally come to a head. After attorneys from both sides made their final, impassioned statements to the jury this past Tuesday, deliberations lasted for just over 21 hours on what could be one of the most important legal decisions the industry has seen in years.
While nine jurors in California attempt to turn days worth of allegations and testimony into a binding legal verdict, the Apple/Samsung patent fiasco finally came to a head in Samsung’s native South Korea. According to the
Recent Comments